Search Results - "Flaherty, Lawrence E."

Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group by ATKINS, Michael B, HSU, Jessie, LEE, Sandra, COHEN, Gary I, FLAHERTY, Lawrence E, SOSMAN, Jeffrey A, SONDAK, Vernon K, KIRKWOOD, John M

“…Phase II trials with biochemotherapy (BCT) have shown encouraging response rates in metastatic melanoma, and meta-analyses and one phase III trial have…”
Get full text

Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933 by Lee, Sylvia M., Moon, James, Redman, Bruce G., Chidiac, Tarek, Flaherty, Lawrence E., Zha, Yuanyuan, Othus, Megan, Ribas, Antoni, Sondak, Vernon K., Gajewski, Thomas F., Margolin, Kim A.

“…BACKGROUND Aberrant Notch activation confers a proliferative advantage to many human tumors, including melanoma. This phase 2 trial assessed the antitumor…”
Get full text

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma by McDermott, David F, Regan, Meredith M, Clark, Joseph I, Flaherty, Lawrence E, Weiss, Geoffery R, Logan, Theodore F, Kirkwood, John M, Gordon, Michael S, Sosman, Jeffrey A, Ernstoff, Marc S, Tretter, Christopher P G, Urba, Walter J, Smith, John W, Margolin, Kim A, Mier, James W, Gollob, Jared A, Dutcher, Janice P, Atkins, Michael B

“…The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN)…”
Get full text

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis by Tarhini, Ahmad A, Kang, Ni, Lee, Sandra J, Hodi, F Stephen, Cohen, Gary I, Hamid, Omid, Hutchins, Laura F, Sosman, Jeffrey A, Kluger, Harriet M, Eroglu, Zeynep, Koon, Henry B, Lawrence, Donald P, Kendra, Kari L, Minor, David R, Lee, Carrie B, Albertini, Mark R, Flaherty, Lawrence E, Petrella, Teresa M, Streicher, Howard, Sondak, Vernon K, Kirkwood, John M

“…BackgroundThe impact of immune-related adverse events (irAEs) occurring from adjuvant use of immunotherapy and of their management on relapse-free survival…”
Get full text

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma by Clark, Joseph I, Singh, Jatinder, Ernstoff, Marc S, Lao, Christopher D, Flaherty, Lawrence E, Logan, Theodore F, Curti, Brendan, Agarwala, Sanjiv S, Taback, Bret, Cranmer, Lee, Lutzky, Jose, Luna, Theresa L, Aung, Sandra, Lawson, David H

“…Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an…”
Get full text

Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group by SONDAK, Vernon K, LIU, P.-Y, NOYES, R. Dirk, FLAHERTY, Lawrence E, TUTHILL, Ralph J, KEMPF, Raymond A, UNGER, Joseph M, SOSMAN, Jeffrey A, THOMPSON, John A, WEISS, Geoffrey R, REDMAN, Bruce G, JAKOWATZ, James G

“…Patients with clinically negative nodes constitute over 85% of new melanoma cases. There is no adjuvant therapy for intermediate-thickness, node-negative…”
Get full text

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609 by Tarhini, Ahmad A, Lee, Sandra J, Hodi, F Stephen, Rao, Uma N M, Cohen, Gary I, Hamid, Omid, Hutchins, Laura F, Sosman, Jeffrey A, Kluger, Harriett M, Eroglu, Zeynep, Koon, Henry B, Lawrence, Donald P, Kendra, Kari L, Minor, David R, Lee, Carrie B, Albertini, Mark R, Flaherty, Lawrence E, Petrella, Teresa M, Streicher, Howard, Sondak, Vernon K, Kirkwood, John M

“…Phase III adjuvant trials have reported significant benefits in both relapse-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI)…”
Get full text

Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma by Lao, Christopher D, Moon, James, Ma, Vincent T, Fruehauf, John P, Flaherty, Lawrence E, Bury, Martin J, Martin, William G, Gross, Howard, Akerley, Wallace, Hopkins, Judith O, Patel, Sapna P, Sondak, Vernon K, Ribas, Antoni

“…Cell cycle inhibition is an established therapeutic approach for some cancers. A multicenter, single-arm, phase 2 trial (ClinicalTrials.gov identifier…”
Get full text

A phase 2 trial of complete resection for stage IV melanoma by Sosman, Jeffrey A., Moon, James, Tuthill, Ralph J., Warneke, James A., Vetto, John T., Redman, Bruce G., Liu, P. Y., Unger, Joseph M., Flaherty, Lawrence E., Sondak, Vernon K.

“…BACKGROUND: On the basis of retrospective experience at individual centers, it appears that patients with stage IV melanoma who undergo complete resection have…”
Get full text

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group by Flaherty, Lawrence E, Othus, Megan, Atkins, Michael B, Tuthill, Ralph J, Thompson, John A, Vetto, John T, Haluska, Frank G, Pappo, Alberto S, Sosman, Jeffrey A, Redman, Bruce G, Moon, James, Ribas, Antoni, Kirkwood, John M, Sondak, Vernon K

“…High-dose interferon (IFN) for 1 year (HDI) is the US Food and Drug Administration-approved adjuvant therapy for patients with high-risk melanoma. Efforts to…”
Get full text

A Phase 2 Trial of Complete Resection for Stage IV Melanoma: Results of Southwest Oncology Group Clinical Trial S9430 by SOSMAN, Jeffrey A, MOON, James, TUTHILL, Ralph J, WARNEKE, James A, VETTO, John T, REDMAN, Bruce G, LIU, P. Y, UNGER, Joseph M, FLAHERTY, Lawrence E, SONDAK, Vernon K

“…On the basis of retrospective experience at individual centers, it appears that patients with stage IV melanoma who undergo complete resection have a favorable…”
Get full text

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer by Budd, George T, Barlow, William E, Moore, Halle C F, Hobday, Timothy J, Stewart, James A, Isaacs, Claudine, Salim, Muhammad, Cho, Jonathan K, Rinn, Kristine J, Albain, Kathy S, Chew, Helen K, Burton, Gary V, Moore, Timothy D, Srkalovic, Gordan, McGregor, Bradley A, Flaherty, Lawrence E, Livingston, Robert B, Lew, Danika L, Gralow, Julie R, Hortobagyi, Gabriel N

“…To determine the optimal dose and schedule of anthracycline and taxane administration as adjuvant therapy for early-stage breast cancer. A 2 × 2 factorial…”
Get full text

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer by Smith, David C, Redman, Bruce G, Flaherty, Lawrence E, LI, Lang, Strawderman, Myla, Pienta, Kenneth J

“…Objectives. To test the use of 1 mg/day of oral diethylstilbesterol (DES) as a treatment for patients with advanced prostate cancer who had failed primary…”
Get full text

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697) by Agarwala, Sanjiv S, Lee, Sandra J, Yip, Waiki, Rao, Uma N, Tarhini, Ahmad A, Cohen, Gary I, Reintgen, Douglas S, Evans, Terry L, Brell, Joanna M, Albertini, Mark R, Atkins, Michael B, Dakhil, Shaker R, Conry, Robert M, Sosman, Jeffrey A, Flaherty, Lawrence E, Sondak, Vernon K, Carson, William E, Smylie, Michael G, Pappo, Alberto S, Kefford, Richard F, Kirkwood, John M

“…Purpose To test the efficacy of 4 weeks of intravenous (IV) induction with high-dose interferon (IFN) as part of the Eastern Cooperative Oncology Group regimen…”
Get full text

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438) by MARGOLIN, Kim A, MOON, James, FLAHERTY, Lawrence E, LAO, Christopher D, AKERLEY, Wallace L, OTHUS, Megan, SOSMAN, Jeffrey A, KIRKWOOD, John M, SONDAK, Vernon K

“…Signaling pathway stimulation by activating mutations of oncogenes occurs in most melanomas and can provide excellent targets for therapy, but the short-term…”
Get full text

High frequency of brain metastases after adjuvant therapy for high‐risk melanoma by Samlowski, Wolfram E., Moon, James, Witter, Merle, Atkins, Michael B., Kirkwood, John M., Othus, Megan, Ribas, Antoni, Sondak, Vernon K., Flaherty, Lawrence E.

“…The incidence of CNS progression in patients with high‐risk regional melanoma (stages IIIAN2a‐IIIC) is not well characterized. Data from the S0008 trial…”
Get full text

Targeted therapies Improved outcomes for patients with metastatic melanoma by Sondak, Vernon K, Flaherty, Lawrence E

“…Recently published phase III trials involving interleukin-2, ipilimumab and vemurafenib redefine 'standard-of-care' for metastatic melanoma and demonstrate…”
Get full text

New Options for the Adjuvant Treatment of Cutaneous Melanoma? by Weise, Amy M., Flaherty, Lawrence E.

“…High-dose interferon is the current standard of care for the adjuvant treatment of high-risk cutaneous melanoma. Despite numerous clinical trials using…”
Get full text

A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331) by Samlowski, Wolfram E, Moon, James, Tuthill, Ralph J, Heinrich, Michael C, Balzer-Haas, Naomi S, Merl, Stuart A, DeConti, Ronald C, Thompson, John A, Witter, Merle T, Flaherty, Lawrence E, Sondak, Vernon K

“…Imatinib mesylate (Gleevec) was evaluated as a treatment for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) based on the identification of…”
Get full text

High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190 by KIRKWOOD, J. M, IBRAHIM, J. G, SONDAK, V. K, RICHARDS, J, FLAHERTY, L. E, ERNSTOFF, M. S, SMITH, T. J, RAO, U, STEELE, M, BLUM, R. H

“…Pivotal trial E1684 of adjuvant high-dose interferon alfa-2b (IFNalpha2b) therapy in high-risk melanoma patients demonstrated a significant relapse-free and…”
Get full text